GM1 gangliosidosis

Reuben Matalon MD PhD (Dr. Matalon of University of Texas Medical Branch has no relevant financial relationships to disclose.)
Kimberlee Michals-Matalon PhD (Dr. Michals-Matalon of the University of Houston has no relevant financial relationships to disclose.)
Lisvania M Delgado BS (Ms. Delgado of University of Texas Medical Branch has no relevant financial relationships to disclose.)
Kacey Hart BS (Ms. Hart of University of Texas Medical Branch has no relevant financial relationships to disclose.)
Raphael Schiffmann MD, editor. (Dr. Schiffmann, Director of the Institute of Metabolic Disease at Baylor Research Institute, received research grants from Amicus Therapeutics, Protalix Biotherapeutics, and Shire.)
Originally released November 4, 1993; last updated February 4, 2016; expires February 4, 2019

This article includes discussion of GM1 gangliosidosis, familial neurovisceral lipoidosis, generalized gangliosidosis, Landing disease, pseudo-Hurler disease, Tay-Sachs disease with visceral involvement, infantile variant of GM1 gangliosidosis, juvenile variant of GM1 gangliosidosis, adult variant of GM1 gangliosidosis, and chronic variant of GM1 gangliosidosis. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.

Overview

GM1 gangliosidosis is caused by a deficiency of beta-galactosidase-1. Three different phenotypes are known, with infantile being the most severe. The gene for beta-galactosidase-1 (GBL1) is located on the short arm of chromosome 3, and specific mutations are responsible for the different phenotypes. In this article, the authors cite therapeutic approaches in animal models using chemical chaperones, adeno-associated virus (AAV)-mediated gene therapy, and intracerebral stem cell therapy. Recent efforts have focused on exploring the effect of various pharmacological chaperones on the activity of the mutant enzyme in the different alleles.

Key points

 

• GM1 gangliosidosis is a lysosomal storage disorder.

 

• There are several phenotypes: infantile, juvenile, and adult.

 

• There is a Morquio-like phenotype.

Historical note and terminology

Ganglioside storage diseases are a group of heterogeneous inherited disorders characterized by progressive neurologic deterioration and the intraneuronal accumulation of gangliosides and their complex metabolites. Landing and colleagues first recognized gangliosidosis as a distinct entity (Landing et al 1964). The associated enzymatic deficiency of beta-galactosidase-1 was first identified in the brain, liver, spleen, and kidney and shortly thereafter in white blood cells (Okada and O'Brien 1968). In 1976, a variant of Morquio disease with spondyloepiphyseal dysplasia, keratan sulfate in urine, and beta-galactosidase-1 deficiency was described (O'Brien et al 1976). Because this enzyme deficiency is different than that in Morquio A disease, the Morquio with beta-galactosidase deficiency has been referred to as Morquio B.

The molecular basis of the phenotypes of beta-galactosidase-1 deficiency has become clearer following the cloning of the GBL1 gene. The gene for beta-galactosidase-1 (GLB1) maps to the short arm of chromosome 3 and contains 16 exons (Oshima et al 1988). The mutations that give the phenotype of GM1 gangliosidosis are different than those in Morquio B (Oshima et al 1988). The crystal structure of human beta-galactosidase gives clearer insight regarding the molecular defects of beta-galactosidase and the disease-causing mutations (Ohto et al 2012).

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.